The supplement updates the exchange ratio and ownership percentages for the merger, but does not change the vote mechanics or meeting date. The key event to watch is the December 4, 2026 shareholder vote; approval requires a simple majority. If approved, the merger is expected to close in Q1 2027, subject to the PIPE closing and other conditions.
Drug in focus
CMMB drug pipeline →nebokitug
◆ Mixed Named in this DEFA14A- Impact
- Phase
- Phase 2 (complete); preparing Phase 3
- Time to market
- At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
- Next catalyst
- None dated
What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 11 $1.35entry
- T+1 · 5d ago +3.70%α +4.06% · $1.40
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Chemomab Therapeutics filed a DEFA14A supplement to its proxy statement/prospectus for the December 4, 2026 special meeting to approve the merger with Scipher Medicine. The supplement discloses that on November 3, 2026, Scipher purchased 932,203 ADSs from Chemomab for $1.1 million via an at-the-market offering, and that Scipher issued up to $1.1 million in additional convertible notes. These transactions update the expected Domestication Exchange Ratio to approximately 0.168 shares of Chemomab Parent per ADS and provide updated pro forma financials reflecting the new capital structure.
Key Financial Metrics
Key Facts
- Scipher purchased 932,203 ADSs from Chemomab at $1.18 per ADS for gross proceeds of approximately $1.1 million on November 3, 2026.
- Scipher issued up to $1.1 million in Additional Notes under Amendment No. 3 to the 2026 CNPA, with $858,612 issued as of November 3, 2026.
- The expected Domestication Exchange Ratio is updated to approximately 0.0021 per share (0.168 per ADS), based on 8,988,503 ADSs outstanding as of November 6, 2026.
- The special meeting to vote on the merger remains scheduled for December 4, 2026; the record date is October 29, 2026.
- The merger is expected to close in Q1 2027, subject to shareholder approval and other conditions including a $30 million minimum PIPE investment.
- Pro forma combined net loss for the six months ended June 30, 2026 is $23.9 million; for the year ended December 31, 2025 it is $39.3 million.
- Chemomab Israel shareholders are expected to own approximately 26.7% of the combined company after the merger and PIPE, down from 32% pre-PIPE.
- The filing updates risk factors regarding dilution and control by Scipher securityholders.
Financial Impact
Chemomab received $1.1 million gross ($1,042,000 net) from the ADS sale to Scipher. Scipher issued up to $1.1 million in Additional Notes. The combined company pre-money valuation is $150 million, with a $30-50 million PIPE concurrent with closing.
Risk Factors
- The merger may not close if shareholder approval is not obtained or other conditions (including the $30 million PIPE) are not met.
- If the merger fails, Chemomab may need to raise additional funds and could owe a termination fee of up to $2 million.
- Existing Chemomab shareholders face significant dilution, owning only ~26.7% of the combined company post-merger and PIPE.
- The CVR milestones for nebokitug are contingent and currently assessed as remote; no value is attributed to them in the pro forma.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001493152-26-051035 |
| Document: 0001493152-26-051035-index-headers.html | 0001493152-26-051035 |
| Document: 0001493152-26-051035-index.html | 0001493152-26-051035 |
| Document: 0001493152-26-051035.txt | 0001493152-26-051035 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Viewing Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers